The classification problem this dataset addresses is distinguishing patients with acute myeloid leukemia (AML) according to their prognosis after treatment (remission or relapse of disease). Most of the patients enter complete remission after treatment, but a significant number of them experience relapse with resistant disease.
Platform: Affymetrix GeneChip Human Genome U95 Version [1 or 2] Set HG-U95A
- remission (remission): 28 examples (51.9%)
- relapse (relapse): 26 examples (48.1%)
Number of genes: 12625 Number of samples: 54
Predictive accuracy with 10-fold cross validation (classifying using the best projection with eight attributes):
Following are the three best-ranked visualization with eight, six and four attributes in respect to the visualization score, that is, visualizations where examples from different diagnostic classes are best separated: